Search for content, post, videos

Marketing approval for Novo Nordisk

novo nordisk headquarters

Novo Nordisk has announced the European Medicines Agency  marketing approval of the mylife YpsoPump insulin pump for use with prefilled pump cartridge NovoRapid PumpCart.

The approval is a key milestone for the collaboration between Novo Nordisk and Ypsomed and their goal to deliver innovative care solutions that improve the lives of people with diabetes. With its icon-based touch screen, mylife YpsoPump by Ypsomed is an insulin pump, designed to simplify therapy, which is fully compatible with NovoRapid PumpCart by Novo Nordisk, the first prefilled pump cartridge with an insulin analogue that has been specifically designed for insulin pumps.

“Insulin pump therapy can be an effective option for helping some people with diabetes, particularly those living with type 1 diabetes, however, operating a traditional insulin pump, and manually filling the insulin reservoir, can be complex and time-consuming,” says Dr Mark Evans, lecturer and honorary consultant in medicine at the University of Cambridge. “Given these factors, and the burden put upon health systems to train patients to use traditional pumps, efforts to simplify the process are truly welcomed.”

NovoRapid PumpCart contains NovoRapid (insulin aspart), a rapid-acting insulin from Novo Nordisk, and is a 1.6 ml prefilled pump cartridge specifically designed to make insulin pump therapy more convenient for some people with diabetes and the healthcare professionals caring for them. It is compatible with insulin pump mylife YpsoPump by Ypsomed and has also been available with Roche Diabetes Care’s Accu-Chek Insight insulin pump since November 2014 in select EU markets.

“Our partnerships with Ypsomed and Roche Diabetes Care enable us to offer new options designed to simplify insulin pump therapy for people living with diabetes and the healthcare professionals who manage their care,” said Christian Kanstrup, senior vice president, marketing, medical affairs and stakeholder engagement at Novo Nordisk.

NovoRapid PumpCart is currently available in the following EU markets for use with the Accu-Chek Insight pump: United Kingdom, Sweden, Austria, Denmark, Netherlands, Germany, France, Czech Republic and Italy.

mylife YpsoPump received authorisation for use with prefilled pump cartridge NovoRapid PumpCart on 24 June 2016. Healthcare professionals interested in knowing in which countries mylife YpsoPump will be made available should contact Ypsomed directly.